FR
EN

SQY Therapeutics reports initial dystrophin restoration and reductions in muscle injury biomarkers in the Phase 1/2a AVANCE-1 trial in Duchenne muscular dystrophy

Read article

SQY Therapeutics wins the Innovation Award at the 2026 Entrepreneurs Yvelines Awards

SQY Therapeutics opens a path toward personalized treatments for patients with ultra-rare Duchenne mutations

The Pulmonary Route as a Non-Invasive Alternative for Systemic Administration of Tricyclo-DNA Antisense Oligonucleotides (tcDNA-ASO)

SQY Therapeutics Inaugurates Its New Research & Development Laboratory. A Decisive Step Toward Therapeutic Innovation for Rare Diseases.

SQY Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for SQY51 for the Treatment of Duchenne Muscular Dystrophy

SQY Therapeutics announces completion of the first part of phase 1/2a clinical trial AVANCE-1 and initiation of the second part with recurrent administrations of SQY51